It's a claim that surprises most people: in a properly conducted randomised controlled trial, light therapy outperformed a leading antidepressant for major depression. Not marginally — significantly. And when combined, both together outperformed either alone. For seasonal affective disorder, where the biological case for light therapy is even more direct, the implications are at least as compelling.
This isn't wellness marketing. It's the finding of a randomised controlled trial published in JAMA Psychiatry in 2016 by Raymond Lam and colleagues — one of the most rigorous studies ever conducted on depression and light therapy.
What the Trial Actually Found
The study enrolled 122 adults with major depressive disorder. Over eight weeks, participants received one of four treatments: light therapy alone, an antidepressant alone, light therapy plus antidepressant, or placebo. The results were striking.
Light therapy produced remission in 43.8% of participants. The antidepressant produced remission in 19.4%. The combination of both achieved 58.6% remission. Placebo: 30.0%.
Light therapy didn't just match the drug. It outperformed it significantly, while producing far fewer side effects. The combination was the most effective approach overall.
Why This Doesn't Get More Attention
There's no commercial incentive to publicise light therapy's effectiveness. Pharmaceutical companies fund drug trials and marketing. Nobody holds a patent on morning light. The result is that millions of people receive antidepressants as a first-line SAD treatment when clinical guidelines in Canada and Scandinavia — where SAD research has been most active — recommend light therapy first.
The UK's NICE guidelines acknowledge light therapy as an option but don't specifically recommend it over medication, leaving many GPs uncertain about what to advise. In practice, prescribing a pill is faster than explaining light therapy protocols.
The Important Caveats
This isn't a simple "light is better than drugs" argument. A few important qualifications.
The Lam trial used specifically timed, morning light therapy — 30 minutes at the right spectrum, in the right window after waking. Using a SAD lamp at random times of day, or with the wrong spectrum, would not produce these results.
It's also worth noting the difference between clinical SAD and the winter blues — both respond to light, but the severity, treatment threshold, and clinical approach differ.
For people with moderate to severe depression, antidepressants remain an important treatment option. The Lam trial studied major depressive disorder broadly — the evidence for light therapy in seasonal affective disorder is equally strong, with an even more direct biological rationale.
And for anyone experiencing symptoms of depression, speaking to a GP or mental health professional is always the right starting point. We're not suggesting you make treatment decisions based on a blog post.
Why Spectrum Matters for Outcomes
The clinical trials that established light therapy's effectiveness used broad-spectrum white light at 10,000 lux. That works. But it works because it contains some 480–490nm melanopsin-activating light within the broad spectrum — not because broad white light is intrinsically therapeutic.
Targeting 480–490nm directly — the melanopsin peak — achieves the same biological effect at a fraction of the intensity. Lower intensity means less glare, less discomfort, and easier integration into a morning routine. You're more likely to actually use it.
For a comparison of what the current SAD lamp market actually delivers, see our review of every SAD lamp on the market.
This is the approach behind LightHealth. Not 10,000 lux of broad white light, but precision spectral delivery at the wavelength your circadian system actually responds to.
Read about the LightHealth approach to seasonal wellbeing.
LightHealth products are in development. Join the early access list and be first to know when we launch.
